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Stress granules, processing bodies,  
and RNA triage
Life is stressful. Eukaryotic cells have evolved sophisticated 
strategies to combat a barrage of cellular stresses, which include 
heat shock, chemical exposures, oxidative stress, and even 
aging (Morimoto, 2011). Under stress, a cell’s top priority is 
to conserve energy and divert cellular resources toward survival 
and eventual recovery. One way to conserve resources is to limit 
the translation of cellular mRNAs and focus on producing just 
the essential proteins needed for survival (Lindquist, 1981). 
In eukaryotic cells, a powerful way of accomplishing this 
switch is by rapidly assembling nontranslating mRNAs and 
their associated RNA-binding proteins into aggregate-like struc-
tures. These structures, called RNP granules, include process-
ing bodies (P-bodies) and stress granules (SGs; Anderson and 
Kedersha, 2008).
The localization, modification, and decay of mRNAs in 
RNP granules play a critical role in the cellular stress response 
(Anderson and Kedersha, 2008). P-bodies and SGs are sites 
where nontranslating mRNAs, as well as factors involved in 
translation repression and mRNA decay, preferentially localize 
when translation is stalled or impeded. SGs form in response to 
a variety of environmental stresses that impede translation 
(e.g., heat shock, glucose deprivation, oxidative stress, etc.) and 
may represent localized zones of stalled translation initiation 
(Kedersha et al., 2005; Kwon et al., 2007; Anderson and Kedersha, 
2008). Indeed, SGs can be induced by pharmacologically inhib-
iting translation initiation, depleting mRNA translation initia-
tion factors, or even by overexpressing certain RNA-binding 
proteins (Anderson and Kedersha, 2008).
Like SGs, P-bodies are also RNP granules that serve key 
roles in mRNA homeostasis (Jain and Parker, 2013). In contrast 
to SGs, P-bodies are not associated with regulation of transla-
tion initiation, but rather represent sites of mRNA degradation, 
translation repression, nontranslating mRNAs, and RNA-binding 
proteins. P-bodies mediate mRNA decay, including nonsense-
mediated decay (NMD), and RNA interference by serving as 
sites of colocalization for RNA processing components such 
as the RNA decapping machinery, including the decapping 
enzymes DCP1/2; the activators of decapping Dhh1/RCK/p54, 
Pat1, Scd6/RAP55, and Edc3; the Lsm1-7 complex; and the 
exonuclease Xrn1 (Parker and Sheth, 2007). The mobilization 
of RNAs and RNA-binding proteins to RNP granules is dif-
ferentially regulated (Jain and Parker, 2013; Shah et al., 2013) 
after induction by various sources of cellular stress. Although 
SGs and P-bodies are distinct foci of RNA-RNP localization, 
they can physically interact to facilitate the shuttling of RNA 
and protein species from one spatially localized compartment to 
another. Hence, SG and P-body formation are powerful protec-
tive mechanisms through which eukaryotic cells can dynami-
cally triage RNA metabolism as they fight for survival from 
environmental stress (Anderson and Kedersha, 2008).
How to build an SG: the role of RNA-
binding proteins with prion-like domains
In response to an unexpected cellular stress, RNP granules form 
very rapidly (within minutes) to minimize mRNA damage 
(Fig. 1; Chernov et al., 2009; Buchan et al., 2011). How are 
Amyotrophic lateral sclerosis (ALS) is a fatal human neu-
rodegenerative disease affecting primarily motor neurons. 
Two RNA-binding proteins, TDP-43 and FUS, aggregate 
in the degenerating motor neurons of ALS patients, and 
mutations in the genes encoding these proteins cause 
some forms of ALS. TDP-43 and FUS and several related 
RNA-binding proteins harbor aggregation-promoting 
prion-like domains that allow them to rapidly self-associate. 
This property is critical for the formation and dynamics of 
cellular ribonucleoprotein granules, the crucibles of RNA 
metabolism and homeostasis. Recent work connecting 
TDP-43 and FUS to stress granules has suggested how 
this cellular pathway, which involves protein aggregation 
as part of its normal function, might be coopted during 
disease pathogenesis.
Stress granules as crucibles of ALS pathogenesis
Yun R. Li,1,3 Oliver D. King,4 James Shorter,2 and Aaron D. Gitler3
1Medical Scientist Training Program and 2Department of Biochemistry and Biophysics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia,  
PA 19104
3Department of Genetics, Stanford University School of Medicine, Stanford, CA 94305
4Department of Cell and Developmental Biology, University of Massachusetts Medical School, Worcester, MA 01655
© 2013 Li et al. This article is distributed under the terms of an Attribution–Noncommercial–
Share Alike–No Mirror Sites license for the first six months after the publication date (see 
http://www.rupress.org/terms). After six months it is available under a Creative Commons 
































Published April 29, 2013
JCB • VOLUME 201 • NUMBER 3 • 2013 362
A unifying feature of the vast majority of known yeast prion 
proteins is the presence of a modular prion domain (Wickner 
et al., 2000). This domain enables the protein to which it is ap-
pended to form self-templating amyloid fibrils (Fig. 2, steps a–d; 
Li and Lindquist, 2000). Accessing the aggregated or prion form 
usually leads to a reduction of the protein’s function. Impor-
tantly, these aggregation-associated phenotypes are reversible, 
and sophisticated disaggregation machinery helps to regulate 
the disassembly of prion aggregates (Glover and Lindquist, 
1998; Shorter and Lindquist, 2004; Cashikar et al., 2005).
Strikingly, many of the RNA-binding proteins that make 
up SG and P-bodies harbor prion-like domains. Of the top 100 
yeast proteins that harbor validated or predicted prion domains, 
10% contain an RNA-recognition motif (RRM) domain, and 
24% are annotated with a gene ontology (GO) accession of 
“RNA binding,” several of which have been shown to con-
tribute to SG and P-body formation. In the human proteome, 
there are 250 proteins with computationally predicted prion-
like domains (King et al., 2012), of which 12% harbor an 
RRM domain and 20% are annotated with a GO accession 
of RNA binding (Table 1). Besides RNA binding and closely 
related categories, other functional categories enriched for pro-
teins with prion-like domains include chromosome organiza-
tion (GO:0051276), embryo development (GO:0009790), and 
protein-binding transcription factor activity (GO:0000988; GO 
Slim categories with <1,000 genes and an enrichment p-value 
<105 by a Fisher’s exact test even when RNA-binding proteins 
were excluded). The striking overrepresentation of prion-like do-
mains in RNA-binding proteins strongly suggests an important 
role of this domain in RNA-binding protein function. Indeed, 
prion-like domains are ideal tools for RNA-binding proteins to 
deploy. Because they are able to self-associate, these domains 
confer the ability to rapidly coalesce to form P-bodies and SGs, 
and indeed many other RNP granules that serve as “crucibles” 
for many facets of RNA metabolism (Gilks et al., 2004). For 
example, TIA1, an RNA-binding protein that is required for SG 
formation in mammals, contains a prion-like domain that drives 
SG assembly (Gilks et al., 2004). Moreover, deletion of the 
prion-like domain from Lsm4 and Pop2 reduces their ability to 
accumulate in P-bodies in yeast (Reijns et al., 2008).
RNA-binding proteins equipped with prion-like domains 
are able to recruit target mRNAs with their RNA-binding do-
mains (e.g., RRM, KH) and then round them up into RNP 
granules using their prion-like domains, where they wait for 
the cellular stress to subside. The reversibility of prion-like ag-
gregation allows the RNP granules to rapidly dissociate when 
the stress dissipates, releasing the sequestered mRNAs and 
translation machinery to resume their normal functions. The 
precise machinery that drives SG disassembly remains to be 
fully elucidated, and it should be noted that metazoa lack direct 
homologues of Hsp104, which drives rapid prion dissolution in 
yeast (Shorter and Lindquist, 2004). However, it is not clear in 
the context of SGs whether prion-like domains access a highly 
stable amyloid form (Fig. 2). Indeed, the prion-like domains 
of some RNA-binding proteins access a more labile and dy-
namic cross- structure, which can be tightly regulated by 
phosphorylation of serine residues in the prion-like domain 
RNA-binding proteins and their associated RNAs able to co-
alesce to form SGs with such alacrity? Intriguingly, many SG- and 
P-body–associated RNA-binding proteins harbor prion-like 
domains (Gilks et al., 2004; Couthouis et al., 2011, 2012; Gitler 
and Shorter, 2011; King et al., 2012; Kim et al., 2013). A “prion-
like domain” simply refers to a protein domain with a similar 
amino acid composition to yeast prion domains, which enable 
various yeast prion proteins such as Sup35 or Rnq1 to access 
the prion state (King et al., 2012). Prions are proteins capable of 
forming infectious amyloid conformations, which self-template 
their own assembly (Fig. 2, steps a–d). Prions can transmit heri-
table phenotypic changes from one cell to another, between indi-
viduals, or even between species (Shorter and Lindquist, 2005; 
Colby and Prusiner, 2011). In mammals, prions are the patho-
genic agent responsible for deadly spongiform encephalopathies. 
Interestingly, yeast cells can transmit infectious phenotypes 
using a similar self-templating prion mechanism, and these 
phenotypes can sometimes even be beneficial, allowing yeast 
cells to adapt to and cope with varying environment conditions 
(Shorter and Lindquist, 2005; Malinovska et al., 2013).
Figure 1. SGs and P-bodies are sites of RNA triage. Exposure to cellular 
stress can trigger a stress response that stalls translation initiation, result-
ing in the formation of SGs. SGs are dynamic cytoplasmic RNA–protein 
complexes that contain RNA-binding proteins, mRNAs, and translation 
initiation factors. When stress exposure dissipates, SGs disassemble and 
mRNA translation resumes. Nontranslating mRNAs can also be directed to 
P-bodies, distinct RNA-protein granules that are sites of stalled translation 
and mRNA degradation. SGs and P-bodies are differentially regulated 
and form independently, but they can and often do interact with each 
other. TDP-43, FUS, and other RNPs (e.g., TAF15, EWSR1, hnRNPA1, 
and hnRNPA2B1) reside predominantly in the nucleus, but stress exposure 
can trigger their recruitment to SGs. The implications for the recruitment of 
TDP-43, FUS, and others to SGs are explored in Fig. 3.
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pathogenic aggregates (Fig. 2, steps i–l). At least two RNA-
binding proteins that harbor prion-like domains, TDP-43 and 
FUS, can contribute to deadly human neurodegenerative dis-
eases when mutated or when subcellular localization and aggre-
gation becomes unchecked. And, as discussed next, these two 
proteins may represent just the tip of the iceberg for aggregation-
prone RNA-binding proteins connected with neurodegenerative 
disease (King et al., 2012).
TDP-43 and FUS: an emerging role  
for RNA-binding proteins in 
neurodegenerative disease
ALS is a fairly common neurodegenerative disease caused by 
a selective loss of motor neurons from the brain and spinal cord 
(Cleveland and Rothstein, 2001). Typically, this neurodegenera-
tion leads to paralysis and death within 2–5 years of diagnosis. 
Like several other neurodegenerative diseases, the degenerating 
neurons of ALS patients are characterized by the accumulation of 
protein aggregates (Forman et al., 2004). In 2006 it was discov-
ered that the major protein component of many of these inclu-
sions is the 43-kD TAR-DNA–binding protein (TDP-43; Arai 
et al., 2006; Neumann et al., 2006). TDP-43 is a DNA- and RNA-
binding protein with two RRMs and a C-terminal prion-like 
domain, which is also referred to as a Gly-rich domain (Cushman 
et al., 2010). TDP-43 normally localizes to the nucleus, where it has 
roles in regulating splicing and mRNA stability (Lagier-Tourenne 
et al., 2010; Da Cruz and Cleveland, 2011). In the degenerat-
ing neurons and glia of ALS patients, TDP-43 is depleted from 
the nucleus and accumulates in large cytoplasmic aggregates. 
TDP-43 also undergoes several disease-specific posttranslational 
(Fig. 2, steps a, g, and h; Sun et al., 2011; Han et al., 2012; Kato 
et al., 2012). Importantly, these labile fibrillar assemblies en-
able a phase transition to hydrogel structures that are capable of 
retaining RNAs and RNA-binding proteins that are specific to 
the protein forming the gel (Han et al., 2012; Kato et al., 2012). 
In Caenorhabditis elegans, P granules exhibit liquid-like behav-
iors, including dripping, wetting, fusion, rapid dissolution, and 
condensation (Brangwynne et al., 2009). More broadly, inter-
actions between diverse multivalent macromolecules (including 
multidomain proteins and RNA) can elicit sharp liquid–liquid 
demixing phase transitions that give rise to micrometer-scale 
liquid droplets in aqueous solution, which can also be regu-
lated by phosphorylation (Li et al., 2012). These phase tran-
sitions likely underpin RNP granule biogenesis and represent 
a fundamental mechanism for organizing non–membrane-
bound compartments in the cytoplasm (Fig. 2, steps a, g, and h; 
Hyman and Simons, 2012; Weber and Brangwynne, 2012). 
Similar self-organizing events underpin the de novo formation 
of subnuclear organelles, such as Cajal bodies (Kaiser et al., 
2008; Shevtsov and Dundr, 2011). Remarkably, certain RNA-
binding proteins, such as TDP-43 and FUS, which have been 
linked to neurodegenerative diseases, are also required for for-
mation of nuclear gems, subnuclear organelles that likely par-
ticipate in small nuclear RNP (snRNP) biogenesis and are lost 
in amyotrophic lateral sclerosis (ALS; Yamazaki et al., 2012; 
Tsuiji et al., 2013).
The ability to rapidly form RNP granules by deploying 
prion-like domains does not come without a price. Indeed, the 
ability to phase transition to hydrogel-like structures likely also 
simultaneously increases the propensity to form more intractable, 
Figure 2. Prion and prion-like domains en-
code diverse conformational states and fold-
ing trajectories. Typically, prion and prion-like 
domains (depicted in blue, green, and red) 
populate a dynamic equilibrium comprised 
of soluble intrinsically unfolded monomers 
and molten oligomers (step a). These mol-
ten oligomers can subsequently evolve into 
multiple conformational states. In one trajec-
tory, molten oligomers reorganize into more 
structured amyloidogenic oligomers (step b), 
which ultimately convert into a stable amyloid 
form (step c), which can self-template assembly 
(step d) and become infectious (i.e., a prion). 
Amyloidogenic oligomers can also cluster to 
form large pathological aggregates (step e), 
which might slowly convert to amyloid (step f). 
Alternatively, molten oligomers can partition 
into partially structured forms with dynamic 
cross- structures that exhibit liquid-like prop-
erties (step g), and can rearrange further into 
labile cross- fibrils with gel-like properties 
(step h). These liquid and gel-like collectives 
are likely critical structural components of vari-
ous non–membrane-bound organelles includ-
ing SGs and nuclear gems. Importantly, these 
transitions to liquid- and gel-like structures are 
readily reversible (steps a, g, and h). We sug-
gest, however, that these structures are also 
prone to morph into amyloidogenic oligomers 
(step i), pathological nonamyloid aggregates 
(step j and k), and even stable self-templating 
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aggregates, it raises the question of whether loss of TDP-43 
nuclear function, a gain of toxic function in the cytoplasm, or 
some combination of both contributes to disease (Fig. 3). Shortly 
modifications, including hyperphosphorylation, ubiquitination, 
and cleavage (Kwong et al., 2007). Because TDP-43 is both 
depleted from the nucleus and accumulates in cytoplasmic 
Table 1. Human RNA-binding proteins with prion-like domains




Prion domain score Prion domain 
rank
P-bodies and/or  
SGs?
Neurodegenerative disease?
TNRC6A  + 42.1 9 +
FUS + + 38.5 12 + ALS, FTLD
ATXN1  + 35.5 15 SCA1
TAF15 + + 33.2 22 + ALS, FTLD
EWSR1 + + 32.3 25 + ALS, FTLD
HNRPDL + + 31.5 27
HNRNPD + + 30.7 29.5
HNRNPA2B1 + + 29.9 32 + IBMPFD
ILF3  + 29.8 33
HNRNPUL1  + 28.5 37
HNRNPA1 + + 28.2 38 + IBMPFD, ALS
HNRNPAB + + 27.8 39
HNRNPA3 + + 27.2 41 + C9orf72 ALS/FTLD
TARDBP + + 26.5 43 + ALS, FTLD
HNRNPU  + 24.9 49
TIA1 + + 23.4 53 + Welander distal myopathy 
HNRNPA1L2 + + 22.8 57
HNRNPH1 + + 22.2 63
DDX5  + 21.2 73 +
PSF + + 20.8 79 FTLD
HNRNPA0 + + 20.5 81
HNRNPH2 + + 17.5 101
DAZ2 + + 16.2 119
RBM14 + + 16.0 122
CSTF2 + + 15.7 126
TNRC6C  + 15.4 128 +
SOX2  + 15.0 135
CAPRIN1  + 14.9 136 +
DROSHA  + 14.8 137
DDX17  + 14.8 139
DAZ3 + + 14.6 144.5
DAZ2 + + 14.6 144.5
DAZ1 + + 14.1 148
HNRNPH3 + + 14.0 151
CSTF2T + + 14.0 153
CELF4 + + 13.8 156
TIAL1 + + 13.6 162 +
RBM33 + + 12.9 178
DLX2  + 12.5 188
DAZAP1 + + 11.7 203
SUPT6H  + 11.6 206
ATXN2  + 10.2 227 + SCA2, ALS
DHX9  + 10.1 230
PSPC1 + + 10.0 231
GAR1  + 9.4 235
SF1  + 9.4 236
FUBP1  + 9.2 237
EIF4G3  + 8.5 243 +
EIF4G1  + 8.3 246 + PD
49 human RNA-binding proteins (containing the Pfam RRM [PF00076] and/or annotated with the GO term for RNA-binding [GO:0003723]) also harbor predicted 
prion-like domains. Prion score, based on Alberti et al. (2009), indicates the maximum log-likelihood ratio for prion-like amino acid composition vs. non–prion-like 
amino acid composition in any 60 consecutive amino acid window contained in a region parsed as prion-like by the hidden Markov model. Prion domain rank is 
from 21,873 human proteins, 250 of which had positive prion score. Localization to P-bodies or SGs is based on literature searches, especially Buchan and Parker 
(2009). Human disease connections for select proteins are indicated.
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prion domains in yeast prion proteins, a bioinformatics approach 
recently identified novel “prion-like” domains in the C-terminal 
domain of TDP-43 (amino acids 277–414) and in the N-terminal 
domain of FUS (amino acids 1–239; Cushman et al., 2010). 
Disease-associated mutations in these domains might cause 
disease by increasing the propensity of TDP-43 or FUS to 
aggregate. Indeed, the ALS-linked TDP-43 mutations, Q331K 
and M337V, fall in the prion-like domain and directly accelerate 
TDP-43 misfolding (Johnson et al., 2009).
Beyond TDP-43 and FUS, more than 40 additional RNA-
binding proteins in the human proteome also contain predicted 
prion-like domains (Table 1), raising the intriguing possibility that 
these proteins may also contribute to ALS and related neuro-
degenerative diseases (King et al., 2012). Indeed, TAF15 and 
EWSR1 are now connected with ALS and FTLD, where they 
were found to be aggregated in the cytoplasm of degenerat-
ing neurons (Couthouis et al., 2011, 2012; Neumann et al., 
2011). Mutations in TAF15 and EWSR1 are connected with 
sporadic ALS and accelerate misfolding of the pure protein 
in vitro (Couthouis et al., 2011, 2012). Moreover, in a subset 
of FTLD cases, PSF is aberrantly localized to the cytoplasm 
of oligodendrocytes and forms detergent-insoluble structures 
(Seyfried et al., 2012). A mutation in TIA1, a critical protein 
for SG formation, was recently found as the cause of Welander 
distal myopathy, an adult-onset autosomal dominant disease 
associated with distal limb weakness (Klar et al., 2013). Muta-
tions in the prion-like domains of hnRNPA1 and hnRNPA2/B1 
cause familial forms of inclusion body myopathy with fronto-
temporal dementia, Paget’s disease of bone, and ALS (some-
times called “IBMPFD/ALS”), and mutations in the prion-like 
domain of hnRNPA1 are also connected with familial and 
sporadic ALS (Kim et al., 2013). Disease-linked mutations in 
the prion-like domain of hnRNPA1 and hnRNPA2/B1 intro-
duce a potent steric zipper, which can form two self-comple-
mentary  sheets that comprise the spine of an amyloid fibril 
(Sawaya et al., 2007). The mutant steric zippers dysregulate 
and accelerate hnRNPA1 and hnRNPA2/B1 misfolding (Kim 
et al., 2013). Indeed, these mutations likely divert hnRNPA1 
and hnRNPA2/B1 away from physiological folding trajecto-
ries connected with RNP granule assembly (Fig. 2, steps a, g, 
and h) and promote formation of pathological amyloid forms 
(Fig. 2, steps a–d). Finally, mislocalized hnRNPA3 was recently 
identified as a constituent of cytoplasmic inclusions in ALS and 
FTLD cases harboring C9orf72 hexanucleotide repeat expan-
sions (Mori et al., 2013). Collectively, these findings suggest 
that RNA-binding proteins with prion-like domains stand on the 
edge of a precipice that can collapse to yield devastating neuro-
degenerative disorders.
The discovery of prion-like domains in TDP-43, FUS, and 
many more RNA-binding proteins presents a conundrum: if the 
prion-like domains of these proteins directly contribute to their 
dysfunction and cause lethal neurodegenerative diseases, why 
are these domains so highly conserved through evolution? 
It seems that the aggregation-prone nature of these proteins is 
harnessed so that they can perform essential cellular functions, 
such as being able to rapidly coalesce to form SGs under situa-
tions of cellular stress (Fig. 2, steps a, g, and h).
after the discovery of a major role of TDP-43 in ALS pathological 
lesions, in 2008 human geneticists converged on the TDP-43 
gene (TARDBP), identifying more than 30 different TDP-43 
mutations in sporadic and familial ALS patients (Lagier-
Tourenne et al., 2010). Together, these discoveries, and the 
convergence of pathology and genetics on TDP-43, com-
pletely revolutionized ALS research and focused attention on 
RNA-binding proteins and RNA processing pathways (Lagier-
Tourenne et al., 2010). Beyond ALS, TDP-43 was also found to 
be the proteinaceous building blocks of the cytoplasmic inclu-
sions found in a large subset of frontotemporal lobar degenera-
tion (FTLD) patients, and indeed this subtype is now subsumed 
under the classification FTLD-TDP (Mackenzie et al., 2011).
Almost immediately after the identification of TDP-43 
mutations as a cause of ALS, another RNA-binding protein, 
remarkably similar to TDP-43, was implicated in ALS patho-
genesis. Mutations in FUS (fused in sarcoma; also known as 
TLS, translocated in liposarcoma) were identified in familial 
and sporadic ALS patients (Lagier-Tourenne et al., 2010). Like 
TDP-43, FUS is normally a nuclear protein, and ALS-causing 
FUS mutations result in cytoplasmic FUS accumulations. Inter-
estingly, these inclusions do not contain TDP-43, and TDP-43 
inclusions do not contain FUS (Vance et al., 2009).
Identification of prion-like domains  
in TDP-43, FUS, and beyond
A fascinating and potentially revolutionary new concept is 
emerging in several neurodegenerative diseases. It involves the 
transmission or propagation of protein aggregates from cell to 
cell and from one brain region to another during the onset and 
progression of disease (Aguzzi and Rajendran, 2009; Cushman 
et al., 2010; Frost and Diamond, 2010). Compelling in vitro and 
in vivo experimental evidence now indicates that diverse neuro-
degenerative disease proteins are able to enter cells, seek out 
their cognate proteins, and template their conversion to aggre-
gated conformations. This “bucket-brigade”-like form of propa-
gation helps to explain how disease pathology seems to emerge 
from epicenters in the brain and spread along anatomically 
interconnected brain regions during disease progression (Braak 
et al., 2003; Ravits and La Spada, 2009). It should also be noted 
that cases in which disease pathology initially arises at discon-
nected brain regions does not necessarily exclude a prion-like 
mechanism of spread. Pathology that originates in discontigu-
ous brain regions could represent independent nucleation sites 
from which pathology can then spread. Thus, even pathology 
that originates at disparate sites could be caused by prion-like 
nucleation that is then followed by propagation.
But what is the molecular basis for the prion-like spread 
of neurodegeneration? How can and do these proteins access 
an altered conformation that is able to recruit and then template 
the conversion of nonaggregated protein to the altered disease-
associated conformation? Prion proteins in fungi accomplish 
this by using prion domains (Fig. 2, steps a–d). These domains 
are typically enriched in uncharged polar amino acids (such 
as asparagine, glutamine, and tyrosine) and glycine (Alberti 
et al., 2009; King et al., 2012). Based on the salient features of 
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owing to diverse genetic and environmental factors, or perhaps 
even aging itself. For example, ALS-linked TDP-43 muta-
tions promote persistent cytoplasmic aggregation of the mutant 
TDP-43 and result in increased SG association (Fig. 3), which 
does not appear to be reversible after stress induction (Liu-
Yesucevitz et al., 2010). Indeed, wild-type (WT) TDP-43 is also 
prone to localize to SGs and access aggregated structures that 
are not readily cleared after severe stress (Parker et al., 2012). Cells 
expressing mutant TDP-43 appear to either exhibit attenuated SG 
formation or be prone to abnormal SG assembly (Liu-Yesucevitz 
et al., 2010; McDonald et al., 2011). Although TDP-43 does not 
appear to be necessary for SG formation, siRNA knockdown of 
WT TDP-43 has been shown to significantly reduce average 
SG size, arguing that TDP-43 may play a direct role in the SG 
assembly process (McDonald et al., 2011).
FUS, like TDP-43, demonstrates stress-induced SG local-
ization, and ALS-linked FUS variants are more prone to localize 
to SG compartments (Bosco et al., 2010; Dormann et al., 2010; 
Gal et al., 2011; Sun et al., 2011). Indeed, it has been proposed 
that the mechanism through which FUS mutations act to pro-
mote ALS may be directly related to mislocalization of FUS to 
the cytoplasm, leading to abnormal interactions with SGs and 
consequent dysregulation of SG physiology (Bosco et al., 2010; 
Sun et al., 2011). Most of the bona fide ALS-causing FUS muta-
tions cluster in a small region in the extreme C-terminal domain 
of FUS, which encodes a PY-NLS motif (Dormann et al., 2010; 
Zhang et al., 2012). This motif is both necessary and sufficient 
TDP-43 and FUS associate with SGs
Not only do TDP-43 and FUS possess prion-like domains that 
appear to mediate pathological protein aggregation, both pro-
teins also harbor conserved RRMs. The RRMs of TDP-43 and 
FUS contribute to both proteins localizing to SGs and P-bodies 
(Colombrita et al., 2009) and might also synergize with the 
prion-like domains to promote aggregation. Such interactions 
are crucial for physiological regulation of RNA stability, pro-
cessing, and decay, as well as pathological cellular stress re-
sponses. For example, cytoplasmic TDP-43 inclusions have 
been shown to colocalize with several SG markers (e.g., TIA-1, 
TIAR) in cultured cells and primary neurons in response to cel-
lular stress, and in postmortem samples from ALS and FTLD 
patients (Liu-Yesucevitz et al., 2010; Wolozin, 2012). In addi-
tion to ALS and FTLD, TIA-1 has been show to interact with 
tau and to localize with neurofibrillary pathology in Alzheimer’s 
disease and other tauopathies (Vanderweyde et al., 2012).
TDP-43 and FUS are nuclear proteins that can quickly be 
shuttled to the cytoplasm upon stress induction. Once in the 
cytoplasm, they rapidly associate with SGs (Ayala et al., 2008b; 
Dormann et al., 2010). In normal cells, once the instigating 
stress resolves, SGs dissolve and TDP-43 and FUS return to the 
nucleus. Thus, the nuclear-cytoplasmic shuttling of TDP-43 and 
FUS, as well as their association with cytoplasmic SGs, are 
physiological and reversible processes.
However, in pathological conditions, the nuclear-cytoplasmic 
shuttling of TDP-43 and FUS becomes dysregulated, possibly 
Figure 3. How TDP-43 and FUS might inter-
face with SGs during pathogenesis. (A) In nor-
mal neurons, TDP-43 and FUS are localized 
to the nucleus, and SGs form and dissipate 
normally. TDP-43 or FUS localization becomes 
abnormal during ALS pathogenesis and may 
interface with SGs in several different (and 
non-mutually exclusive) ways: (B) TDP-43 or 
FUS exit from the nucleus and begin to accumu-
late in the cytoplasm as preinclusions, where 
they interact and might colocalize with SGs. 
Here, TDP-43 and FUS might become modified 
by kinases, proteases, and ubiquitin-modifying 
enzymes, which are all present in SGs. These 
pathological modifications could accelerate 
TDP-43 and FUS aggregation or prevent return 
to the nucleus. Thus, SGs could serve as an 
obligate conduit for TDP-43 and FUS aggrega-
tion. Ubi, ubiquitin. (C) TDP-43 and FUS ag-
gregation in the cytoplasm might interfere with 
SG function, perhaps by interfering with their 
ability to regulate RNAs targeted to these struc-
tures. (D) TDP-43 and FUS might be required in 
the nucleus for the regulation of SG genes, and 
therefore depletion from the nucleus could lead 
to a dysregulation of SG genes and decreased 
SG formation and function.
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Dewey et al., 2011, 2012; Wolozin, 2012). Together, this model 
describes how the stress-provoked phenotypes of cells express-
ing pathological FUS and TDP-43 may result from accumula-
tion of these RNPs in SGs, consequently inhibiting physiological 
stress responses.
It remains unclear, however, whether cytoplasmic mislo-
calization and SG aggregation of TDP-43 or FUS is causative in 
ALS/FTLD patients, or whether these cytopathological pheno-
types represent the end stage consequence of cellular stress 
responses within degenerating neurons. Evidence for the former 
has come from experiments demonstrating that SG formation 
itself during cell stress response appears to be cytoprotective 
by helping to shift translation toward heat shock proteins 
(Lindquist, 1981; Wolozin, 2012). Notably, mRNAs that are 
highly translated during stressful growth conditions often use 
noncanonical translational mechanisms (Spriggs et al., 2008). 
For instance, mRNAs containing internal ribosome entry sites 
(IRES) require trans-activating factors for ribosomal recruit-
ment, including hnRNPA1 and PCBP2, which are both recruited 
to SGs (Bonnal et al., 2005; Guil et al., 2006; Fujimura et al., 
2010). Among IRES-containing transcripts are many keys to 
cell proliferation, survival, and apoptosis. Here, the aggregation 
of mutant FUS or TDP-43 in SGs may inhibit or “out-compete” 
the localization of RNAs encoding antiapoptotic factors or pro-
liferative factors required to promote cell recovery after cell 
injury. Therefore, exuberant accumulation of aggregation-prone 
FUS or TDP-43 in SGs might inhibit translation of mRNAs 
critical to cell survival and recovery, and consequently increase 
the rate of cell death and neuron loss (Nevins et al., 2003).
It is important to note that TDP-43 and FUS must bind 
RNA and aggregate to confer toxicity in multiple model sys-
tems. Indeed, mutation of the RRMs of FUS and TDP-43 to 
forms that are incompetent for RNA binding greatly reduces 
toxicity without affecting aggregation (Elden et al., 2010; Voigt 
et al., 2010; Sun et al., 2011; Daigle et al., 2013). Thus, mere 
misfolding or aggregation driven by a prion-like domain is not 
sufficient for toxicity. These observations indicate the finding 
that RNA binding might enable TDP-43 and FUS to access 
specific misfolded conformations that are intrinsically toxic. 
Alternatively, or in addition, RNA-binding activity might en-
able TDP-43 and FUS to sequester essential RNAs and other 
RNA-binding proteins in inclusions. Because TDP-43 and FUS 
regulate the splicing of myriad mRNAs with large introns that 
are critical for neuronal viability (Polymenidou et al., 2011; 
Colombrita et al., 2012; Lagier-Tourenne et al., 2012), it seems 
probable that sequestration of these mRNAs might be particu-
larly damaging for specific neurons. Thus, strategies to release 
these RNAs from aggregated FUS or TDP-43 traps could have 
therapeutic utility.
Model 2: Loss of function in SGs model. A GOF 
model for TDP-43 and FUS in ALS pathogenesis would be con-
sistent with the broad and apparently pervasive role of toxic 
protein aggregation across several neurodegenerative diseases 
(Forman et al., 2004). However, it is not clear how the forma-
tion of insoluble fibrils of FUS and TDP-43 causes neuronal 
dysfunction and death. Moreover, FUS- or TDP-43–containing 
SGs can disperse in healthy neurons after stress induction, 
for FUS nuclear localization, and the most pathogenic mutations 
in FUS have the most severe effect on binding to the nuclear 
import factor karyopherin-2 and consequent FUS nuclear 
localization (Dormann et al., 2010; Zhang et al., 2012). The 
most aggressive ALS-linked FUS mutations such as P525L and 
R495X (which removes the entire PY-NLS) are associated with 
earlier age of ALS onset, cause FUS to be localized entirely to 
the cytoplasm, and greatly perturb binding to karyopherin-2 
(Dormann et al., 2010; Zhang et al., 2012). Once FUS starts to 
accumulate in the cytoplasm, it has a greater propensity to asso-
ciate with SGs, and various environmental stressors accentuate 
this process (Dormann et al., 2010; Fig. 3).
Models of TDP-43/FUS in SG biology
The molecular mechanisms by which FUS and TDP-43 muta-
tions contribute to ALS/FTLD are not fully understood. The 
formation of TDP-43– or FUS-positive subcellular aggregates 
that colocalize with SGs in neurons from ALS patients supports 
the hypothesis that cellular mistargeting of these RRM-containing 
proteins has a key role in ALS pathophysiology (Fig. 3). The 
loss of TDP-43/FUS from the nucleus or their increased cyto-
plasmic localization to SGs could serve as a critical pathway 
for ALS. Hence, in the context of ALS pathophysiology, two 
central questions remain: (1) Do mutations in TDP-43 and FUS 
cause a loss or gain of function in these proteins? and (2) Is 
altered SG assembly a consequence or cause of TDP-43 and 
FUS mislocalization? The answers to these questions will en-
hance our mechanistic understanding of ALS and will help guide 
the development of potential therapeutic strategies.
Several models have been proposed to explain the role of 
FUS, TDP-43, and SG biology in ALS/FTLD pathogenesis. We 
will briefly highlight evidence supporting three hypotheses that 
are not mutually exclusive, and it is probable that they even syn-
ergize to varying degrees in specific cases of ALS and FTLD.
Model 1: Gain of function in SGs model. The 
gain-of-function (GOF) toxicity model asserts that pathological 
TDP-43 or FUS aggregate in SGs, impeding normal SG-mediated 
RNA homeostasis (Fig. 3 B). In this model, the physiological 
localization of TDP-43 to SGs during cell stress is a conse-
quence of normal stress response but is not required for normal 
SG assembly, an observation in line with SG formation in the 
absence of TDP-43 expression (Colombrita et al., 2009; Liu-
Yesucevitz et al., 2010; McDonald et al., 2011). In contrast, the 
excessive SG localization of FUS and TDP-43 (Bosco et al., 
2010; Liu-Yesucevitz et al., 2010) might drive dysregulated 
assembly of inappropriate fibrillar aggregates (Johnson et al., 
2009; Sun et al., 2011), which perturb the localization of mes-
senger RNPs (mRNPs) required for RNA processing and decay, 
thereby interfering with RNA sorting. If this process continues 
unabated, ultimately the assembly of translation initiation com-
plexes could be affected by preventing the increase in local con-
centration of mRNAs and translation factors (Buchan and 
Parker, 2009). Finally, insoluble FUS and TDP-43 aggregates 
alter SG dynamics even after stress resolution (Parker et al., 
2012), resulting in SG persistence as has been observed in cells 
expressing ALS-associated TDP-43 or FUS mutants (Bosco 
et al., 2010; Dormann et al., 2010; Liu-Yesucevitz et al., 2010; 
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to repress the transcription of SP-10 required for spermatogen-
esis in mice (Tan and Manley, 2010). Furthermore, TDP-43 has 
been shown to play an important role in regulating the splicing 
of alternative isoforms of proteins, including cystic fibrosis 
transmembrane regulator (CFTR), apolipoprotein A-II, and sur-
vival of motor neuron (SMN), possibly related to its association 
with several other protein involved in splicing (e.g., SC35; Buratti 
et al., 2001; Mercado et al., 2005; Fiesel et al., 2012). Thus, 
depletion of nuclear pools of TDP-43 and FUS is likely to impact 
these essential functions. Moreover, ALS-linked mutations might 
even subtly impair nuclear TDP-43 or FUS function in a man-
ner that is selectively toxic for motor neurons upon aging and 
may not even require depletion of nuclear pools (Polymenidou 
et al., 2011; Lagier-Tourenne et al., 2012; Schwartz et al., 2012; 
Arnold et al., 2013).
Moreover, TDP-43’s role in SG biology may actually depend 
on its nuclear regulation of SG genes (Fig. 3 D). Specifically, the 
role of TDP-43 in SG assembly has recently been shown to strongly 
depend on its regulation of G3BP transcription (Aulas et al., 2012). 
G3BP, a protein required for normal SG assembly, is a transcrip-
tional target of TDP-43 and is severely depleted in TDP-43– 
depleted cells (Dammer et al., 2012). Restoration of G3BP by 
overexpression rescues the SG phenotype observed in TDP-43– 
depleted cells, which suggests that TDP-43 is an upstream 
regulator of G3BP and that this could explain a significant 
proportion of TDP-43’s role in SG dynamics. However, this is 
entirely dependent on TDP-43’s nuclear, not cytoplasmic, func-
tion. It will be important to determine whether restoration of 
FUS and TDP-43 function in the nucleus or cytoplasm, or both, 
is sufficient to rescue neurodegenerative disease phenotypes.
Ataxin 2, SGs, and disease: integrating 
environmental stress and disease?
Ataxin 2 is another SG-associated RNA-binding protein that 
contributes to neurodegenerative disease (Elden et al., 2010; 
Orr and Zoghbi, 2007). Ataxin 2 interacts with polyA-binding 
protein (PABP1) to regulate mRNA polyadenylation and is 
required for SG assembly (Kaehler et al., 2012). Ataxin 2 har-
bors a polyglutamine (polyQ) tract and is a member of a family 
of polyQ disease proteins, which include the Huntington’s dis-
ease protein huntingtin. The ataxin 2 polyQ tract normally 
contains 22 or 23 Qs. PolyQ tract expansions >34 Q cause 
spinocerebellar ataxia type 2 (SCA2), an autosomal dominant 
hereditary ataxia (Orr and Zoghbi, 2007). Interestingly, ataxin 2 
has recently been shown to associate with TDP-43 in an RNA-
dependent manner and to modify TDP-43 cytotoxicity in multiple 
model systems (Elden et al., 2010). Ataxin 2 protein accumu-
lates abnormally in discrete foci in the degenerating motor neu-
rons of ALS patients, structures likely to represent SGs and 
harbor other key SG components. Ataxin 2 has also been con-
nected to ALS through genetics. Intermediate-length ataxin 2 
polyQ expansions (27–33 Qs), longer than normal but not past 
the threshold for SCA2, were recently associated with increased 
risk for ALS (Elden et al., 2010). Together, these findings sug-
gest mechanistic links between the diseases ALS and SCA2 and 
implicate a key building block of SGs, ataxin 2, in disease 
pathogenesis. It is also tempting to interpret these findings by 
which suggests, superficially at least, that their aggregation 
alone is not sufficient for cytotoxicity. Indeed, it will be impor-
tant to determine whether FUS and TDP-43 localized to SGs 
adopt the same conformation as FUS and TDP-43 in pathologi-
cal inclusions. That is, do FUS and TDP-43 form a continuum 
of aggregated structures, some of which are functional and 
beneficial and others that are toxic and deleterious? The propen-
sity of yeast prion domains to access a range of distinct self-
templating structures, termed strains (Shorter, 2010), suggests 
that FUS and TDP-43 are also likely to access an entire spec-
trum of distinct aggregated conformers that could exert benefi-
cial or deleterious effects (Fig. 2).
Significant cellular damage and death is induced by TDP-
43 or FUS knockdown in neurons, primary cell lines, and model 
organisms, which suggests a loss-of-function (LOF) model 
(Hicks et al., 2000; Ayala et al., 2008a). Moreover, although the 
physiological roles of TDP-43 and FUS are still being clarified, 
two distinct possibilities have been proposed for LOF toxicity. 
Specifically, the nuclear LOF model suggests that the cytoplas-
mic mislocalization of FUS or TDP-43 impedes their ability to 
perform essential nuclear functions, whereas the cytoplasmic 
LOF model emphasizes the fact that FUS or TDP-43 play a 
physiological role in cytoplasmic SGs during cell stress but that 
ALS-associated conformers or mutants have impaired protein–
protein or protein–RNA interactions. Again, these possibilities 
are not mutually exclusive and may synergize to promote ALS 
or FTLD pathogenesis.
The cytoplasmic LOF model suggests that FUS and TDP-43 
are critical mediators of nuclear-cytoplasmic RNA transport and 
shuttling, which affect the physiology of SG formation during 
stressful conditions. TDP-43 has been repeatedly demonstrated to 
have pronounced effects on SG dynamics (Fig. 3 C), as delayed 
formation, reduced size, altered morphology, and limited stability 
of SGs are observed in HeLa cells and neuroblastoma cell lines 
depleted of TDP-43 (McDonald et al., 2011; Aulas et al., 2012).
In addition, WT FUS appears to be recruited to dendrites 
by mGluR5 activation in neurons, where it mediates a rise in 
local RNA content, and FUS-null neurons demonstrate ab-
normal spine morphology and density (Fujii et al., 2005), un-
derscoring that loss of normal FUS function can contribute 
to pathogenesis. The role of FUS in SG biology is still being 
delineated, but FUS has been shown to bind RNAs encoding 
actin-stabilizing proteins such as Nd1-L, which may be impor-
tant for mRNA transport to dendritic spines (Fujii et al., 2005). 
Thus, the subcellular localization of TDP-43 and FUS to SGs 
during stress induction, and subsequent dispersal after stress, 
might indicate that the trafficking of FUS and TDP-43 to SGs is 
cytoprotective and possibly critical for RNA triage and resolu-
tion of translational stall.
Model 3: Nuclear LOF model. Although the cyto-
plasmic LOF model is consistent with many aspects of TDP-43 
and FUS pathological interactions, both proteins have well- 
established important nuclear roles as well, including pre-
mRNA splicing, RNA stability, and transcriptional regulation 
(Lagier-Tourenne et al., 2010). Indeed, TDP-43 was originally 
discovered as a transcriptional repressor that binds to TAR 
DNA of HIV-1 (Ou et al., 1995) and was subsequently found 
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Finally, ataxin 2 and SGs, with their roles in sensing and 
responding to environmental stresses, might help to explain 
the connection between environmental exposures, including 
traumatic injury, and the pathogenesis of ALS and related neu-
rodegenerative disorders. Upon exposure to stress, TDP-43, 
FUS, and other RNA-binding proteins move from the nucleus 
to the cytoplasm and associate with ataxin 2–containing SGs 
(Bosco et al., 2010; Dormann et al., 2010; Liu-Yesucevitz 
et al., 2010). Once the stress subsides, SGs no longer aggregate, 
and the RNA-binding proteins translocate back to the nucleus. 
This repeated cycle of aggregation and disaggregation, over the 
course of a lifetime, perhaps more so when exposed to specific 
environmental exposures and traumas, can become misregu-
lated and can lead to the improper cytoplasmic localization of 
one or more of these proteins. This failure to restore nuclear 
localization of these proteins could cause the subsequent dis-
ease pathology (Fig. 4). Age-dependent breakdown in cellular 
proteostasis may lead to further defects in maintaining SG pro-
tein quality control and likely underpins the late-onset aspect of 
disease. In individuals with genetic risk factors for ALS, such 
as intermediate-length ataxin 2 polyQ expansions, the thresh-
old for disease-causing responses to such stresses might be 
lower than normal. Genetic screening of contact sport athletes 
and military personnel for genetic risk factors such as ataxin 2 
polyQ expansions might be an important way of prescreening 
individuals who could potentially be at an elevated risk for more 
severe clinical consequences from such injuries.
Potential therapeutic approaches to 
mitigate SG-mediated processes
This connection between ataxin 2, TDP-43, and SG biology 
illuminates the concept that the pathogenesis of ALS and re-
lated diseases might be tightly linked to an ancient core cell 
speculating that the pathogenesis of ALS and related neuro-
degenerative diseases could be intimately tied to SG forma-
tion pathways.
How could different mutations in ataxin 2 (long vs. inter-
mediate length polyQ expansions) contribute to distinct phenotypic 
consequences in SCA2 versus ALS? One potential explanation 
is that intermediate-length polyQ expansions in ataxin 2 result 
in enhanced stress-induced caspase activation, which leads to 
increased TDP-43 pathological modifications, including cleavage 
and hyperphosphorylation (Fig. 4). In surprising contrast, neither 
normal-length nor long, SCA2-length polyQ expansions result in 
this type of stress response (Hart and Gitler, 2012). Given ataxin 
2’s pivotal role in SG assembly and function and the ability of 
polyQ expansions to enhance the interaction between ataxin 2 
and TDP-43, one way that ataxin 2 could link TDP-43 to SGs and 
ALS pathogenesis is by promoting the recruitment of TDP-43 to 
SGs. Once associated with SGs, TDP-43 would be exposed to 
kinases, proteases, and ubiquitin-modifying enzymes, all of which 
are regulators of SG dynamics. This might increase the likeli-
hood that one or more of these enzymes could subject TDP-43 
to modifications such as phosphorylation, cleavage, and ubiqui-
tination, which are all hallmarks of TDP-43 pathology in disease 
(Neumann et al., 2006).
Another way that polyQ expansions in ataxin 2 could con-
tribute to ALS is by hampering the ability of SGs to dissolve 
properly and/or by reducing the efficiency by which TDP-43 re-
turns to the nucleus (Fig. 4 B), with the cumulative effect being 
a greater propensity for TDP-43 to abnormally accumulate in 
the cytoplasm. This concept suggests that ALS pathogenesis is 
deeply rooted in basic cell biology, and a better understanding 
of the regulators of SG assembly and disassembly could pro-
vide new insight into disease mechanisms and suggest novel 
therapeutic approaches.
Figure 4. How ataxin 2 polyQ expansions 
might affect SGs in ALS. Ataxin 2 is a compo-
nent of SGs and is required for their formation 
and function. Pathogenic polyQ expansions 
in ataxin 2 underlie spinocerebellar ataxia 2 
and ALS. (A) SGs form upon cellular stress. 
The ataxin 2 polyQ length is normally 22 Q. 
When the stress dissipates, SGs dissolve. (B) In 
the presence of a pathogenic ataxin 2 polyQ 
expansion, the SGs might be more difficult to 
dissolve, perhaps owing to increased ataxin 2 
stability. Persistent SGs would have a greater 
chance to interface with TDP-43 or FUS in the 
cytoplasm (TDP-43 and FUS normally shuttle 
in and out of nucleus). Thus, increased inter-
actions of TDP-43 or FUS with SGs could lead 
to enhanced pathological modifications, result-
ing in TDP-43 or FUS aggregate formation.
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biological pathway (SG formation), and raises the possibility of 
therapeutic interventions aimed at targeting SGs. First, it may 
be useful to identify factors that promote recruitment of FUS 
and TDP-43 into SGs. If specific inhibitors of interaction be-
tween primary aggregation factors and FUS or TDP-43 could 
be identified, this may be of therapeutic potential. Interest-
ingly, Liu-Yesucevitz et al. (2010) recently showed that stably 
expressed WT and mutant TDP-43 can be coimmunoprecipi-
tated with TIA-1 in HEK293 cells. In addition, this interaction 
appears to be RNA-dependent, as RNase treatment eliminates 
this interaction (Liu-Yesucevitz et al., 2010). Moreover, elimi-
nation of either the first or both RNA-binding domains of 
TDP-43 reduces basal aggregation (Liu-Yesucevitz et al., 2010). 
FUS recruitment to SGs is clearly RNA-dependent, as an engi-
neered FUS mutant lacking the RNA-binding domain showed 
low levels of localization with TIA-1 in response to arsenite 
(Bentmann et al., 2012). Blocking this type of interaction could 
potentially impede SG localization and mitigate disease.
Conclusions
Several emerging links now tie SG assembly and RNA-binding 
proteins with prion-like domains to neurodegenerative disease 
(Gitler and Shorter, 2011; King et al., 2012; Wolozin, 2012; 
Table 1). This convergence suggests that common solutions might 
be developed to mitigate the pathogenesis of several disorders, 
including some forms of ALS, which are caused by dysfunc-
tional RNA and protein proteostasis. For example, although for 
the most part FUS and TDP-43 control the splicing of different 
pre-mRNAs (Polymenidou et al., 2011; Lagier-Tourenne et al., 
2012), there are a small number of genes whose expression 
levels depend on TDP-43 or FUS, including PARK2, KCNIP4, 
and SMYD3, which are essential for neuronal survival and 
function (Lagier-Tourenne et al., 2012). Likewise, genetic mod-
ifiers of TDP-43 and FUS toxicity in yeast display little overlap, 
but there are exceptions (Elden et al., 2010; Sun et al., 2011; 
Armakola et al., 2012). We expect that model organisms will 
play a major role in identifying common solutions for correct-
ing defective RNA and protein proteostasis that is critical for 
developing drugs with broad efficacy.
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